Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 4.4% – Should You Sell?

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price traded down 4.4% during trading on Wednesday . The stock traded as low as $2.37 and last traded at $2.38. 955,137 shares changed hands during mid-day trading, a decline of 36% from the average session volume of 1,482,567 shares. The stock had previously closed at $2.49.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a research report on Friday, November 15th. Needham & Company LLC reissued a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Thursday, December 5th. Finally, The Goldman Sachs Group raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $7.00 to $7.60 in a research report on Monday, November 18th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $10.40.

Autolus Therapeutics Stock Performance

The firm has a fifty day moving average of $3.45 and a 200-day moving average of $3.80. The stock has a market capitalization of $609.36 million, a price-to-earnings ratio of -1.89 and a beta of 1.98.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period last year, the business earned ($0.26) EPS. On average, analysts predict that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP boosted its stake in Autolus Therapeutics by 35.4% during the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after buying an additional 6,330,392 shares in the last quarter. FMR LLC lifted its position in shares of Autolus Therapeutics by 44.6% in the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after acquiring an additional 5,478,706 shares in the last quarter. Great Point Partners LLC grew its position in Autolus Therapeutics by 195.0% during the 2nd quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock worth $11,977,000 after purchasing an additional 2,275,000 shares in the last quarter. Armistice Capital LLC lifted its holdings in shares of Autolus Therapeutics by 33.8% in the second quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock valued at $21,750,000 after purchasing an additional 1,578,000 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Autolus Therapeutics by 74.5% during the second quarter. Bank of New York Mellon Corp now owns 2,531,688 shares of the company’s stock valued at $8,810,000 after buying an additional 1,080,897 shares in the last quarter. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.